Effect Size Analysis of Cipaglucosidase Alfa Plus Miglustat Versus Alglucosidase Alfa in ERT-experienced Adults with Late-onset Pompe Disease in PROPEL (S21.003)

To analyze within-group effect sizes of cipaglucosidase alfa plus miglustat (cipa+mig) and alglucosidase alfa (alg) for efficacy, quality of life (QoL), and biomarker variables in ERT-experienced patients. The randomized, double-blind PROPEL study (ATB200-03; NCT03729362) compared the efficacy and safety of the investigational two-component enzyme replacement therapy (ERT) cipa+mig with alg plus placebo in adults with late-onset Pompe disease (LOPD) ; 77% of patients had received ERT with alg before study entry (median ERT duration 7. 4 years). We analyzed within-group effect sizes of cipa+mig and alg for outcome variables including motor function, lung function and muscle strength tests; patient-reported outcomes/QoL; and biomarkers in ERT-experienced patients. Standardized within-group effect sizes (Cohen's d for correlated measurements from baseline to week 52) were calculated by dividing the mean change from baseline by the standard deviation of the difference scores. ERT-experienced patients remaining on alg (n=30) generally showed worsening (d0. 2) or stability. Patients remaining on alg demonstrated statistically significant within-group worsening for sitting and supine forced vital capacity; slow vital capacity; maximal expiratory pressure; and creatine kinase (CK) and hexose tetrasaccharide (Hex4) levels, and no significant improvements for any outcomes. Patients switching to cipa+mig did not demonstrate significant within-group worsening for any outcomes and showed significant improvements for 6-minute walk distance (absolute and % predicted) ; upper, lower and overall manual muscle test; Patient-Reported Outcomes Measurement Information System (PROMIS) -Fatigue; Physician and Subject Global Impression of Change (five of eight subdomains) ; and CK and Hex4 levels. This analysis shows that ERT-experienced patients with LOPD who switched from alg to cipa+mig treatment achieved improvements in a number of outcomes, highlighting the potential of cipa+mig to become an important treatment option for these patients. Sponsored by Amicus Therapeutics Inc. Disclosure: Dr. Kushlaf has received personal compensation in the range of 500-4, 999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion AstraZeneca Rare Disease. Dr. Kushlaf has received personal compensation in the range of 5, 000-9, 999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Dr. Kushlaf has received personal compensation in the range of 500-4, 999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. Dr. Kushlaf has received personal compensation in the range of 500-4, 999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Kushlaf has received personal compensation in the range of 5, 000-9, 999 for serving on a Speakers Bureau for Sanofi Genzyme. Drago Bratkovic has nothing to disclose. Barry Byrne has received personal compensation in the range of 50, 000-99, 999 for serving as a Consultant for AavantiBio. Barry Byrne has received personal compensation in the range of 5, 000-9, 999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Barry Byrne has received personal compensation in the range of 10, 000-49, 999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vertex. Barry Byrne has received personal compensation in the range of 500-4, 999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Barry Byrne has received personal compensation in the range of 10, 000-49, 999 for serving as an officer or member of the Board of Directors for Muscular Dystrophy Association. Barry Byrne has received intellectual property interests from a discovery or technology relating to health care. Dr. Claeys has nothing to disclose. Jordi Diaz-Manera has nothing to disclose. Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for EcoR1 Capital, LLC. Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Cello Health BioConsulting, previously Defined Health. Dr. Dimachkie has received personal compensation in the range of 10, 000-49, 999 for serving as a Consultant for Sanofi. Dr. Dimachkie has received personal compensation in the range of 10, 000-49, 999 for serving as a Consultant for CSL Behring. Dr. Dimachkie has received personal compensation in the range of 10, 000-49, 999 for serving as a Consultant for Octapharma. Dr. Dimachkie has received personal compensation in the range of 5, 000-9, 999 for serving as a Consultant for ArgenX. Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Spark Therapeutics. Dr. Dimachkie has received personal compensation in the range of 10, 000-49, 999 for serving as a Consultant for RAF-5. Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Houston NeuroCare. Dr. Dimachkie has received personal compensation in the range of 10, 000-49, 999 for serving as a Consultant for Shire. Dr. Dimachkie has received personal compensation in the range of 50, 000-99, 999 for serving as a Consultant for Catalyst. Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Kezar. Dr. Dimachkie has received personal compensation in the range of 10, 000-49, 999 for serving as a Consultant for RaPharma/UCB. Dr. Dimachkie has received personal compensation in the range of 10, 000-49, 999 for serving as a Consultant for ArgenX. Dr. Dimachkie has received personal compensation in the range of 10, 000-49, 999 for serving as a Consultant for Sanofi. An immediate family member of Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Kezar. Dr. Dimachkie has received personal compensation in the range of 10, 000-49, 999 for serving as a Consultant for Catalyst. Dr. Dimachkie has received personal compensation in the range of 5, 000-9, 999 for serving as a Consultant for Takeda. Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for SCHOLAR Rock. Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Jenssen. Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Amazentis / Vandria. Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Spark Therapeutics. Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Roivant. Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for SANEM. Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Medlink. Dr. Dimachkie has received personal compensation in the range of 5, 000-9, 999 for serving as a Consultant for CSL Behring. Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Third Rock. Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Orphazyme. Dr. Dimachkie has received personal compensation in the range of 5, 000-9, 999 for serving as a Consultant for Astellas. Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Janssen. Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Roivant. Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Dianthus. Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for TACT / Treat NMD. Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Cabaletta Bio. Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Clinical Neurological Society of America, Inc. Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Ig Society, Inc. Dr. Dimachkie has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Abcuro. Dr. Dimachkie has received personal compensation in the range of 10, 000-49, 999 for serving on a Scientific Advisory or Data Safety Monitoring board for Covance / Labcorp. The institution of Dr. Dimachkie has received research support from CSL Behring. The institution of Dr. Dimachkie has received research support from Orphazyme. The institution of Dr. Dimachkie has received research support from FDA-OOPD. The institution of Dr. Dimachkie has received research support from NIH. Dr. Dimachkie has received intellectual property interests from a discovery or technology relating to health care. Dr. Dimachkie has received publishing royalties from a publication relating to health care. Priya Kishnani, MD has received personal compensation in the range of 10, 000-49, 999 for serving as a Consultant for Sanofi/Genzyme. Priya Kishnani, MD has received personal compensation in the range of 10, 000-49, 999 for serving as a Consultant for Amicus Therapeutics. Priya Kishnani, MD has received personal compensation in the range of 10, 000-49, 999 for serving as a Consultant for Maze Therapeutics. Priya Kishnani, MD has received personal compensation in the range of 10, 000-49, 999 for serving as a Consultant for JCR Pharmaceutical. Priya Kishnani, MD has received personal compensation in the range of 500, 000-999, 999 for serving as a Consultant for Asklepios Biopharmaceutical Inc. (AskBio). Priya Kishnani, MD has received personal compensation in the range of 0-499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi/Genzyme. Priya Kishnani, MD has received personal compensation in the range of 0-499 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus Therapeutics. Priya Kishnani, MD has received personal compensation in the range of 0-499 for serving on a Scientific Advisory or Data Safety Monitoring board for Baebies, Inc. . The institution of Priya Kishnani, MD has received research support from Sanofi/Genzyme. Priya Kishnani, MD has received research support from Amicus Therapeutics. Priya Kishnani, MD has received intellectual property interests from a discovery or technology relating to health care. Priya Kishnani, MD has received intellectual property interests from a discovery or technology relating to health care. Mark Roberts has nothing to disclose. Dr. Toscano has received personal compensation in the range of 500-4, 999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Dr. Castelli has received personal compensation for serving as an employee of Amicus Therpeutics. Frederick Holdbrook has received personal compensation for serving as an employee of Amicus Therapeutics Inc. . Frederick Holdbrook has stock in Amicus Therapeutics Inc. . Dr. Das has received personal compensation for serving as an employee of Amicus Therapeutics. Dr. Wasfi has received personal compensation for serving as an employee of Amicus Therapeutics. Dr. Wasfi has stock in Amicus Therapeutics. Benedikt Schoser has received personal compensation in the range of 5, 000-9, 999 for serving as a Consultant for Sanofi Genzyme. Benedikt Schoser has received personal compensation in the range of 5, 000-9, 999 for serving as a Consultant for Amicus. Benedikt Schoser has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Bayer. Benedikt Schoser has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Taysha. Benedikt Schoser has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Argenx. Benedikt Schoser has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Alexion. Benedikt Schoser has received personal compensation in the range of 500-4, 999 for serving on a Scientific Advisory or Data Safety Monitoring board for Taysha. Benedikt Schoser has received personal compensation in the range of 500-4, 999 for serving on a Speakers Bureau for Kedrion. Dr. Mozaffar has received personal compensation in the range of 10, 000-49, 999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Mozaffar has received personal compensation in the range of 10, 000-49, 999 for serving as a Consultant for Argenx. Dr. Mozaffar has received personal compensation in the range of 10, 000-49, 999 for serving as a Consultant for Sanofi-Genzyme. Dr. Mozaffar has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Amicus. Dr. Mozaffar has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Modis Therapeutics. Dr. Mozaffar has received personal compensation in the range of 5, 000-9, 999 for serving as a Consultant for UCB/ Ra Pharmaceuticals. Dr. Mozaffar has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Maze Therapeutics. Dr. Mozaffar has received personal compensation in the range of 500-4, 999 for serving as a Consultant for Spark Therapeutics. Dr. Mozaffar has received personal compensation in the range of 5, 000-9, 999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Mozaffar has received personal compensation in the range of 500-4, 999 for serving on a Scientific Advisory or Data Safety Monitoring board for National Institutes of Health. Dr. Mozaffar has received personal compensation in the range of 5, 000-9, 999 for serving on a Speakers Bureau for Argenx. Dr. Mozaffar has received personal compensation in the range of 500-4, 999 for serving as an officer or member of the Board of Directors for Neuromuscular Disease Foundation. The institution of Dr. Mozaffar has received research support from NIH. The institution of Dr. Mozaffar has received research support from Muscular Dystrophy Association. The institution of Dr. Mozaffar has received research support from Sanofi-Genzyme. The institution of Dr. Mozaffar has received research support from Argenx. The institution of Dr. Mozaffar has received research support from Amicus Therapeutics. The institution of Dr. Mozaffar has received research support from Spark Therapeutics. The institution of Dr. Mozaffar has received research support from Audentes Therapeutics. The institution of Dr. Mozaffar has received research support from Cartesian. Dr. Mozaffar has received personal compensation in the range of 500-4, 999 for serving as a Study Section Member with NIH.